House dust mite allergy vaccine - Stallergenes Greer plc

Drug Profile

House dust mite allergy vaccine - Stallergenes Greer plc

Alternative Names: Dust mite extract immunotherapy - Stallergenes Greer plc; HDM immunotherapy - Stallergenes Greer plc; House dust mite immunotherapy - Stallergenes Greer plc

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Greer Laboratories
  • Developer Stallergenes Greer plc
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis in USA (Sublingual, Drops)
  • 17 Mar 2009 Efficacy and adverse events data from a phase I trial in Allergic rhinitis presented at the 65th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2009) ,
  • 31 Dec 2005 Phase-I clinical trials in Allergic rhinitis in USA (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top